Gene Discovered Linked With Type II Diabetes

8 September 1996

Millenium Pharmaceuticals, in collaboration with the Whitehead Institute, USA and Lund University in Sweden, among others, has reported on the mapping of a gene that may be associated with the development of a form of adult-onset diabetes which is linked to the low secretion of insulin. This was reported in the September issue of Nature Genetics.

The identification of the chromosomal location of the gene, referred to as NIDDM2, is thought to be an important advance towards the understanding of the etiology of human diabetes, say the researchers, and may contribute to the development of new therapeutic interventions for the disease.

Over 4,000 individuals from the Botnia region in western Finland, took part in a scanning project. To be included in the study, subjects must have had a minimum of three affected family members, with one having developed the disease before the age of 60, and one before the age of 65. The study ultimately involved 26 families and 217 individuals of whom120 were diabetic patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight